Agios Pharmaceuticals, Inc.
Statements
Cash Flow
Agios Pharmaceuticals, Inc. (AGIO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -57 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49 | -51 | -74 | -59 | -78 | -74 | -99 | -67 | -64 | -74 | -103 | -88 | -86 | -94 | -105 | -68 | -68 | -49 | -121 | -117 | -85 | -84 | -98 | -74 | -71 | -66 | -95 | -67 | -62 | -72 | -100 | -73 | -84 | -133 | -111 | -77 | -88 | -96 | -119 | -57 | -361 | |
| 1.4 | 1.7 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 2.0 | 2.0 | 2.1 | 4.2 | 4.7 | 4.6 | 4.6 | 4.9 | 2.5 | 2.4 | 2.2 | 2.2 | 2.5 | 2.3 | 2.0 | 1.8 | 1.8 | 1.8 | 1.6 | 1.4 | 1.3 | 1.6 | 1.3 | 1.4 | 1.3 | 1.3 | 1.4 | 1.3 | 1.4 | 1.4 | 5.4 | |
| 12 | 9.8 | 11 | 12 | 12 | 13 | 15 | 16 | 24 | 18 | 18 | 19 | 19 | 17 | 20 | 20 | 18 | 17 | 15 | 15 | 12 | 12 | 16 | 11 | 11 | 11 | 10 | 12 | 9.1 | 14 | 9.2 | 12 | 11 | 11 | 11 | 15 | 12 | 14 | 16 | 16 | 58 | |
| 12 | 9.8 | 11 | 12 | 12 | 13 | 15 | 16 | 24 | 18 | 18 | 19 | 19 | 18 | 20 | 20 | 18 | 17 | -1,977 | -26 | 11 | 7.6 | 16 | 11 | 11 | 11 | 10.0 | 12 | 31 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | -6.5 | -20 | 10 | -14 | -0.5 | -24 | -16 | 6.1 | -1.2 | -31 | -0.1 | -1.9 | -13 | -15 | 1.5 | 2.0 | 14 | -21 | -7.6 | -9.2 | 0.7 | -25 | 1.4 | -4.6 | 11 | -26 | 3.8 | -2.7 | 5.6 | -29 | 10 | 45 | -46 | -37 | 8.3 | -0.2 | -4.6 | -39 | -1.0 | -45 | |
| 3.4 | 1.2 | 0.3 | 1.0 | 2.0 | 1.3 | 1.4 | 1.4 | 3.1 | 1.1 | 2.0 | 1.3 | 2.0 | 6.8 | 4.2 | 4.1 | 5.2 | 0.6 | 1.0 | 0.2 | 0.0 | 4.5 | 2.8 | 1.9 | 0.0 | 0.1 | 0.4 | 0.0 | 0.4 | 0.2 | 0.1 | 0.2 | 0.4 | 1.0 | 0.8 | 0.9 | 1.6 | 1.1 | 0.8 | 1.2 | 4.7 | |
| -63 | -78 | 110 | -276 | 66 | 42 | -168 | -96 | 2.8 | -13 | 131 | 64 | 80 | -185 | 108 | 22 | -126 | 71 | 1,874 | -298 | -233 | -94 | -27 | 83 | 104 | 83 | 58 | 47 | 39 | 96 | 125 | 37 | 251 | -49 | 113 | 79 | 96 | 90 | 141 | 40 | 367 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 163 | 4.0 | 4.0 | 273 | 5.3 | 2.6 | 528 | 9.5 | 7.2 | 1.0 | 4.9 | 3.8 | 3.3 | 278 | 5.5 | 1.7 | 3.5 | 0.7 | – | -529 | -254 | -19 | 1.3 | 0.0 | 1.3 | 0.1 | 2.5 | 0.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.6 | 0.2 | -0.1 | -0.1 | -0.1 | -0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 163 | 4.0 | 4.0 | 273 | 5.3 | 2.6 | 528 | 9.5 | 7.2 | 1.0 | 4.9 | 3.8 | 3.3 | 278 | 5.4 | 252 | 3.4 | 0.6 | 7.3 | -503 | -251 | -19 | 1.2 | -0.1 | 1.2 | 0.0 | 2.5 | 0.2 | 1.9 | 0.8 | 5.9 | 1.1 | 2.6 | 4.8 | 1.6 | 0.1 | 4.4 | 2.6 | 2.1 | 3.1 | 12 | |
| 51 | -125 | 40 | -62 | -6.0 | -30 | 262 | -154 | -54 | -86 | 33 | -20 | -1.9 | -0.8 | 8.2 | 207 | -191 | 23 | 1,761 | -919 | -569 | -197 | -123 | 8.5 | 34 | 17 | -35 | -19 | -20 | 24 | 31 | -34 | 169 | -177 | 2.7 | 1.9 | 12 | -3.6 | 24 | -14 | 19 | |
| -52 | -52 | -74 | -60 | -80 | -76 | -100 | -69 | -67 | -75 | -105 | -89 | -88 | -100 | -110 | -72 | -73 | -50 | -122 | -118 | -85 | -89 | -101 | -76 | -71 | -66 | -96 | -67 | -62 | -73 | -100 | -73 | -85 | -134 | -112 | -78 | -90 | -97 | -120 | -59 | -365 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.